age-related disease

By Targets:	AMPK (1) Apoptosis (1) Bcl-2 Family (1) LPL Receptor (1) Mitochondrial Metabolism (1) NAMPT (1) Nuclear Factor of activated T Cells (NFAT) (1) Oxidative Phosphorylation (1) Phospholipase (3) Sirtuin (1) VEGFR (3)
By Research Areas:	Cancer (3) Cardiovascular Disease (4) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (8)

Targets Recommended: Interleukin Related Mas-related G-protein-coupled Receptor (MRGPR) Trk Receptor ROR NEKs Kallikrein Atg4 CGRP Receptor Atg8/LC3 Arp2/3 Complex ATM/ATR sFRP-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147108

Mitochondria degrader-1	Mitochondrial Metabolism	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .

HY-150069

UBX1325	Bcl-2 Family Apoptosis	Metabolic Disease
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .

HY-162269

Nampt activator-5	NAMPT	Neurological Disease
Nampt activator-5 (compound C8) is a potent nicotinamide phosphoribosyltransferase (NAMPT) activator with a K_D value of 6.19 µM. Nampt activator-5 shows a cellular antisenescence effect. Nampt activator-5 promotes the production of NAD ⁺ in the brain and reduces the expression of age-related markers and secretory phenotypes. Nampt activator-5 has the potential for the research of age-related diseases .

HY-153183

Lp-PLA2-IN-12	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .

HY-163403

VEGFR-2-IN-43	VEGFR	Cardiovascular Disease Cancer
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC₅₀ of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-142778

Lp-PLA2-IN-10	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .

HY-110291

A-971432	Others	Neurological Disease
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC₅₀s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .

HY-156781

Sirtuin-1 inhibitor 1	Sirtuin	Metabolic Disease
Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of Sirtuin-1 that plays important roles in obesity-induced diabetes and aging-related diseases .

HY-139464

Q134R	Nuclear Factor of activated T Cells (NFAT)	Neurological Disease
Q134R, a neuroprotective hydroxyquinoline derivative that suppresses nuclear factor of activated T cell (NFAT) signaling. Q134R can across blood-brain barrier. Q134R has the potential for Alzheimer's disease (AD) and aging-related disorders research .

HY-136093

Lixumistat hydrochloride HL271; IM156 hydrochloride; HL156A hydrochloride	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model . Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

Cat. No.	Product Name

HY-L134

Anti-Aging Natural Product Library	192 compounds
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases. Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 192 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

Anti-Aging Natural Product Library

192 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 192 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

Cat. No.	Product Name	Target	Research Area

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.